A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in November 2025.

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...

In June, AstraZeneca once again turned to the Chinese company CSPC Pharmaceuticals, with whom it initially entered into an exclusive license agreement in October 2024 for an early-stage cardiovascular ...

A company that hardly needs an introduction is Eli Lilly, but what has it been up to lately, and what’s its pipeline strategy? Over the past year, Lilly has mixed headline-grabbing science with ...